Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor and Ixazomib in Advanced Sarcoma
NCT03880123Phase 1Withdrawn
- Start
- Nov 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of selinexor in sarcoma, dedifferentiated liposarcoma (DDL), malignant peripheral nerve sheath tumor (MPNST) and 2 more. Primary endpoint: Maximum Tolerated Dose up to 2 years. Planned start Nov 2020; status: withdrawn.
02
Drugs
selinexor
03
Conditions
sarcomadedifferentiated liposarcoma (DDL)malignant peripheral nerve sheath tumor (MPNST)alveolar soft part sarcoma (ASPS)Ewing sarcoma
Beyond the preview
Go deeper on NCT03880123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03880123.